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Abstract: Increasing evidence strongly suggests that bevacizumab compound impacts the 
immunological signature of cancer patients and normalizes tumor vasculature. This study aims to 
investigate the correlation between the clinical response to bevacizumab-based chemotherapy and 
the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood 
mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively 
selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and 
Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were 
monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 
production. A lower activated and resting Treg subset was found in the Bev group compared with 
the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. 
Indeed, clinically responding patients in the Bev group showed a high percentage of non-
suppressive Treg and a significant lower IL10 production compared with non-responding patients 
in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete 
population of effector T cell at T0 independent of the therapeutic regimen. This subset was 
maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab 
could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining 
the circulation of the effector T cells. Results also provide a first rationale regarding the positive 
immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian 
cancer patients. 
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1. Introduction 
Ovarian cancer still accounts for the highest mortality rate among all gynecological malignancies, 
with 295,414 estimated new cases and 184,799 estimated new deaths in 2018 worldwide [1]. 
During the last 10 years, bevacizumab, a monoclonal antibody that binds to vascular endothelial 
growth factor (VEGF), has revolutionized the treatment approach in ovarian cancer, obtaining US Food 
and Drug Administration (FDA)/ European Medicines Agency (EMA) approval in all advanced disease 
settings (multi-treated/compassionate, platinum-resistant/platinum-sensitive recurrent, and primary 
International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV ovarian cancer) 
(www.fda.gov; www.ema.europa.eu). 
The biological mechanism underpinning the clinical efficacy of bevacizumab addition in ovarian 
cancer setting is still a matter of intense investigation. Increasing evidence supports the hypothesis 
that this biological compound modulates patients’ immune system, reducing immunosuppression 
and activating acquired immunity [2]. Several authors have shown the immune effects of 
bevacizumab in multiple cancer settings, such as decrease in patients’ regulatory T cells (Tregs) [3,4] 
and expansion of B and T cells [2]. 
Multi-treated recurrent ovarian cancer patients constitute an extremely fragile disease setting. 
Their immune system is weakened by multiple lines/types of treatment strategies, and the succession 
of therapeutic choices for them is currently discussed without a common consensus among 
oncologists. 
In this study, we show that the clinical response to bevacizumab-based chemotherapy in this 
poor-prognostic disease correlates with improvement of patients’ immune fitness, thus providing 
new evidence that the benefit of such treatment can be ascribed also to its fine immune modulation. 
2. Experimental Section 
2.1. Patient Selection 
This retrospective study received institutional review board (IRB) approval and was carried out 
following the rules of the Declaration of Helsinki of 1975. Patients included in this study were treated 
at the Gynecologic Oncology Unit of the Department of Gynecology, Obstetrics and Urology 
(Sapienza University of Rome, Italy) between 2008 and 2012. Since 2007, all gynecological cancer 
patients admitted in this department have been regularly subjected to donation of peripheral blood 
samples every three cycles of chemotherapy treatment for research purposes with their written 
informed consent. Patients’ peripheral blood mononuclear cells (PBMCs) were regularly collected 
and stored in liquid nitrogen at the Laboratory of Tumor Immunology and Cell Therapy Unit, 
Department of Experimental Medicine (Sapienza University of Rome, Italy—Ethical Committee 
approval, protocol n° 703/2008; date of approval 07/24/2008).  
For this study, 20 consecutive recurrent ovarian cancer patients were retrospectively selected 
from “Sapienza” PBMC sample collection. All available multi-treated platinum-resistant ovarian 
cancer patients subjected to intraperitoneal (i.p.) bevacizumab-based chemotherapy as 
compassionate use were selected (Bev group; 10 patients), together with 10 patients (Ctrl group) that 
received non-bevacizumab-based chemotherapy.  
Inclusion criteria were as follows: primary diagnosis of advanced epithelial serous ovarian 
cancer; having been subjected to at least three previous chemotherapy lines; diagnosis of tumor 
progression confirmed by CT scan; presence of malignant ascites; life expectancy of at least three 
months; and availability of at least three PBMC samples per patient collected during the course of 
bevacizumab-based versus non-bevacizumab-based chemotherapy. Furthermore, patients of the Bev 
group were matched with the Ctrl group patients for age, tumor grading, FIGO stage, type of primary 
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treatment strategy (primary debulking surgery versus neoadjuvant chemotherapy followed by 
interval debulking surgery), tumor residual at first surgery, and type of recurrence at the time of 
blood sampling in order to minimize selection bias and avoid misinterpretations of results.  
Ten patients were identified as the ones that had received i.p. bevacizumab 5 mg/kg every 21 
days immediately after paracentesis for treatment of malignant ascites [5,6] plus intravenous 
(intravenous injection, i.v.) monochemotherapy (cisplatin) [7], while 10 other patients were identified 
as been treated with i.v. monochemotherapy alone (paclitaxel, topotecan, pegylated liposomal 
doxorubicin, cisplatin). Patients’ clinicopathological data were retrieved from clinical charts. Disease 
progression was defined basing on the response evaluation criteria in solid tumors (RECIST) [8]. 
2.2. PBMC Purification 
PBMCs were isolated from 12 to 14 mL of peripheral blood by Ficoll–Hypaque gradient (1077 g/mL; 
Pharmacia LKB, Sweden), obtaining a yield between 10 × 106 and 12 × 106 cells for each drawing and 
cryopreserved until use. Samples were taken before therapy (T0) and after three (III) and six (VI) 
cycles of therapy. 
2.3. Cell Phenotype 
Cell phenotype staining was performed using several directly conjugated monoclonal 
antibodies (MoAbs). T cells were incubated with the anti-CD8-PE-Cy5.5 (RPA-T8 clone), anti-CD3-
PE (UCHT1 clone), anti-CCR7-FITC (150503 clone), and anti-CD45RA-APC (HI100 clone) MoAbs, all 
from Becton Dickinson (Franklin Lakes, NJ, USA). Tregs were stained with the anti-CD25-PE (M-
A251clone), anti-CD45RA-APC (HI100 clone), anti-CD4-FITC (RPA-T4 clone), and anti-FOXP3-Alexa 
647 (259D/C7 clone) MoAbs, all from Becton Dickinson. Cells were incubated with the conjugated 
MoAbs targeting extracellular antigens for 30 min at room temperature (RT) as indicated by the 
manufacturer’s instruction. The staining of intracellular antigen FOXP3 was performed after the cells’ 
permeabilization with the Human FOXP3 Buffer Set (Beckton Dickinson, Franklin Lakes, NJ, USA). 
After washing, at least 1 × 104 events were evaluated using a FACSCanto flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA) running FACSDiva data acquisition and analysis software 
(Becton Dickinson, Franklin Lakes, NJ, USA). The percentages of CD4 and CD8 T cells were calculated 
with respect to the entire CD3 T cell population, while the percentage of Treg was evaluated with 
respect to CD4 T cells. 
2.4. Intracellular Cytokine Staining 
T cells were stimulated with the anti-CD3 (OKT3 clone, 1 μg/mL) (eBioscence, San Diego, CA, 
USA) and anti-CD28 (CD28.2 clone, 5 μg/mL) (BioLegend, San Diego, CA, USA) MoAbs for 16 h at 
37 °C in the presence of Brefeldin (Sigma-Aldrich, St. Louis, MO, USA) (10 μg/mL). The staining of 
IL-10 positive cells was carried out by fixing the cells with 2% paraformaldehyde (Sigma-Aldrich, 
Saint Louis, MO, USA). Cells were than washed with phosphate-buffered saline (PBS) without Ca2+ 
and Mg2+ + 0.5% saponin (Sigma-Aldrich, Saint Louis, MO, USA) + 10% fetal bovine serum (FBS) 
(Sigma-Aldrich, Saint Louis, MO, USA) and incubated for 30 min with anti-IL-10-PE (JES3-19F1 clone) 
(BioLegend, San Diego, CA, USA) MoAb. Cells were analyzed using a FACSCanto flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ, USA) running FACSDiva data acquisition and analysis 
software (Becton Dickinson, Franklin Lakes, NJ, USA). 
2.5. Statistical Analysis 
Statistical analysis was performed using Graphpad Prism version 6 (Graphpad Software, Inc., 
San Diego, CA, USA). 
Descriptive statistics (average and standard deviation) were used to describe different groups 
of continuous data. Student’s t-test was used to compare groups of continuous variables. Groups of 
categorical data were compared using the Fisher’s exact test. Significance is indicated when p ≤ 0.05. 
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3. Results 
3.1. Patients’ Characteristics and Clinical Response 
Twenty patients met all inclusion criteria and were included in the study. Patients’ 
characteristics are listed in Table 1. As a result of patient matching, no differences in terms of 
clinicopathological variables as well the Eastern Cooperative Oncology Group (ECOG) performance 
status could be identified between the Bev group and the Ctrl group. At the time of blood sampling 
for immunological analysis, 12/20 women (60%) presented intraperitoneal tumor progression, 
whereas the remaining 3/20 (15%) and 5/20 (25%) patients were diagnosed with intraperitoneal plus 
retroperitoneal disease worsening and widespread tumor dissemination, respectively.  
From a clinical point of view, and as confirmed by serial Ca125 serum levels (Table S1), 50% 
(10/20) of patients were judged responders to chemotherapy after six cycles of treatment and were 
equally distributed in each group of interventions (5/10 in the Bev group and 5/10 in the Ctrl group).  
Table 1. Patients’ characteristics. 
 Bevacizumab-Treated Patients Control Group p-Value 
Patient n° 10 10  
Age (median, range) 54 years (42y–67y) 48.5 years (45y–71y) 0.845 
ECOG Performance Status   
 
1 1/10 (10%) 2/10 (20%) 
2 7/10 (70%) 5/10 (50%) 
3 2/10 (20%) 3/10 (30%) 
Tumor Grading at primary diagnosis   
0.628 
I 0 0 
II 4/10 (40%) 2/10 (20%) 
III 6/10 (60%) 8/10 (80%) 
FIGO stage at primary diagnosis   
1 IIIC 8/10 (80%) 7/10 (70%) 
IV 2/10 (20%) 3/10 (30%) 
PDS 
NACT 
5/10 (50%) 
5/10 (50%) 
6/10 (60%) 
4/10 (40%) 
1 
RT at first surgery (cm)   
1 =0 9/10 (90%) 8/10 (80%) 
>0 1/10 (10%) 2/10 (20%) 
Type of recurrence at the time of blood sampling   
0.061 
Intraperitoneal only 7/10 (70%) 5/10 (50%) 
intraperitoneal + retroperitoneal 1/10 (10%) 2/10 (20%) 
widespread 2/10 (20%) 3/10 (30%) 
NACT: Neoadjuvant chemotherapy; PDS: Primary Debulking Surgery; RT: Residual Tumor. 
3.2. Bevacizumab-Treated Patients Showed a Different Immunological Signature Compared with the Control 
Group 
To understand whether bevacizumab treatment impacts the immunological status of ovarian 
cancer patients, the modulation of circulating CD4 and CD8 T cells was firstly analyzed in the Bev 
group and the Ctrl group before (T0) and after III and VI cycles of treatments (Figure 1A). Both CD4 
and CD8 T cells played a critical role in the activation of an effective antitumor immunity. CD8 
lymphocytes exerted their cytotoxic activity by eliminating tumor cells, while CD4 T lymphocytes 
sustained and maintained a CD8 T cell response by cytokine production [9]. A deficiency in the 
activation of one of these two populations induced the development of a failed immunity against the 
tumor. Results obtained from the cancer patients showed that therapies did not modify the 
percentage of CD4 and CD8 lymphocytes in both groups at different time points. CD4 T cells were 
significantly higher in the Bev group at T0 and III compared with the Ctrl goup, although this 
difference disappeared at the end of VI cycles. No difference was observed in CD8 T cells between 
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the two groups, although the ratio CD4/CD8 remained high (>1) up to VI cycles in both groups, 
suggesting a predominance of CD4 T cells during therapies.  
CD8 and CD4 T cells were concurrently analyzed for the expression of CCR7 and CD45RA 
molecules, which identify four different lymphocyte subsets: effector (CCR7−CD45RA+), naïve 
(CCR7+CD45RA+), central memory (CCR7+CD45RA−), and effector memory (CCR7−CD45RA−) T cells. 
Analyzing these T cell subpopulations in the Bev and Ctrl group patients, no significant difference 
throughout the treatment in each patient group and between the two groups were found (data not 
shown).  
Finally, the percentage of Tregs was also examined following the expression of CD4, CD25, and 
FOXP3 markers (Figure 1B). In cancers, Tregs represent one of the most important T cell populations 
as they are able to suppress the activation and/or expansion of antitumor CD4 and CD8 T cells 
through cell–cell contact or by cytokine release [10]. A high percentage of Tregs is associated with a 
poor prognosis in different types of solid tumors [11,12]. In our setting of patients, the results 
demonstrated that the Ctrl group showed a significant decrease in total Tregs from T0 to VI cycles 
(36% vs. 31%, p = 0.03), while no difference was found in the Bev group throughout the therapy. Total 
Tregs were further analyzed according to the combined expression of CD25, FOXP3, and CD45RA 
markers, which identifies three important Treg subpopulations [10]: resting Treg 
(CD25+CD45RA+FOXP3+: rTregs), activated Tregs (CD25highCD45RA-FOXP3-: aTregs), and cytokine-
secreting Tregs with no suppressive activity (CD25+CD45RA-FOXP3+: nsTregs). aTreg have been 
described as terminally differentiated cells that rapidly die after exerting their suppressive activity, 
whereas rTreg proliferate and convert into aTreg both in vitro and in vivo [10]. The analysis revealed 
that bevacizumab-treated patients showed a lower percentage of aTregs and rTregs compared with 
the Ctrl group at T0. This difference persisted until III cycles of treatment in the rTreg subset and 
disappeared after VI cycles, suggesting that these patients exhibited a less suppressive 
immunological profile compared with the Ctrl group at the beginning and in particular after III cycles 
of therapies. 
 
Figure 1. Evaluation of CD4 and CD8 T cell in the bevacizumab (Bev) group and the control (Ctrl) 
group by cytofluorimetry. (A) Analysis of the percentage of CD4 and CD8 T cells derived from 
patients belonging to the Bev group and the Ctrl group before (T0) and after III and VI cycles of 
therapies. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were 
identified as CD3+CD8−. (B) Histograms represent the percentage of the different regulatory T cell 
subset (total, active, resting, and nonsuppressive) calculated on CD4+CD25+cells. Bev group and Ctrl 
group are represented with black and grey histograms, respectively. 
3.3. Bevacizumab-Treated Patients Showed a Discrete CD4 Effector T Cell Population throughout the 
Treatment 
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Patients belonging to the Bev group and the Ctrl group were then divided in clinically 
responders (R) and clinically nonresponders (N-R) to therapy according to RECIST (Table S1). The 
modulation of CD4 and CD8 T cell was initially evaluated in R and N-R patients of both groups, 
followed by the analysis of the different T cell subsets (Figure 2). The results demonstrated that the 
CD8 T cells derived from bevacizumab-treated patients were not differently modulated in R and N-
R patients, while the CD4 T cells appeared to be significantly higher in the N-R group at the beginning 
and after VI cycles of treatment. Conversely, in the Ctrl group, the CD8 T cells seemed to be 
significantly higher after VI cycles in the R patients compared with the N-R ones, while no significant 
difference was observed in the CD4 T cell population. 
Lymphocytes were also analyzed according to the expression of CCR7 and CD45RA molecules 
(Figure 3). The results demonstrated that in the Bev group and the Ctrl group, the percentage of CD4 
effector T lymphocytes in R patients was higher compared with N-R patients at T0. This difference 
persisted until the end of the therapies for bevacizumab-treated patients, while it had already 
disappeared after III cycles of therapy in the control group. This suggests that Bev treatment, by 
favoring the normalization of the tumor vasculature [13], improves and sustains the circulation of 
effector T cells. 
The other CD4 T cell subsets and the CD8 T cell populations were not significantly modified by 
treatments (data not shown). 
 
Figure 2. Evaluation of CD4 and CD8 T cells in responding (R) and nonresponding (N-R) patients of 
the bevacizumab-treated group and the control group by cytofluorimetry. CD8 T cells were identified 
by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−. 
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Figure 3. Analysis of CD4 and CD8 T cell subsets were carried out using the anti-CD3, anti-CD8, anti-
CCR7, and anti-CD45RA MoAbs. CD8 T cells were identified by gating the CD3+CD8+ cells, while the 
CD4 T cells were identified as CD3+CD8−. Dot plots show the expression of CD45RA and CCR7 
molecules that identify different T cell subsets (T effector: CD45RA+CCR7−; T central memory: 
CD45RA−CCR7+, T naive: CD45RA+CCR7+, and T effector memory: CD45RA−CCR7−) at T0 and after 
III and VI cycles of therapy. Histograms represent the median values of the percentage of effector T 
cells (CD45RA+CCR7−) of 10 patients (five patients of R and N-R of both Bev group and Ctrl group) ± 
standard deviation. Black and grey columns correspond to responding and nonresponding patients, 
respectively. 
3.4. Tregs Were Modulated in Bevacizumab-Treated Patients during Therapies 
To assess whether the treatment schedule and/or the clinical response could be associated with 
the modulation of the Treg subsets, the percentage of circulating Tregs after III or VI treatment cycles 
were compared with the baseline value at T0, and the analysis was expressed as fold increase 
(%TregIII/%TregT0 or %TregVI/%TregT0) (Figure 4). After III cycles of treatment, the level of the 
entire Treg population was significantly higher in R patients compared with N-R patients in the Bev 
group. This increase was ascribed to the nsTreg subset being significantly higher in R compared with 
N-R patients. These differences between R and N-R patients disappeared after VI cycles of 
bevacizumab treatment. In contrast, the control group did not show any difference in the percentage 
of Tregs between R and N-R patients during therapies, and no difference between the Bev and Ctrl 
patients was observed.  
 
Figure 4. Total and non-suppressive Treg (totTreg and nsTreg, respectively) evaluated as fold increase 
after III or VI cycles of therapy compared with T0 (%TregIII or %TregVI/%TregT0). Black and grey 
columns correspond to Bev group and Ctrl group, respectively. 
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3.4. Bevacizumab-Treated N-R Patients Had Higher Level of IL10+ T Cells Compared to R Patients 
Because IL10, such as TGFβ, is one of the most important cytokines released by Tregs [14] that 
is able to downregulate Th1 cytokine production and block NF-κB activity [15], T cell derived from 
patients in the Bev group were analyzed for their capacity to produce IL10 as intracellular staining 
(Figure 5). These patients exhibited a significant increase in IL10+ cells from T0 up to VI cycles of 
therapy. Analyzing the data as fold increase of the percentage of IL10+ cells after III and VI cycles of 
therapy compared with T0 (%IL10III/%IL10T0 or %IL10VI/%IL10T0) between R and N-R patients, 
significant high levels of IL10 were found in N-R patients after III cycles, suggesting an enhancement 
of the immunosuppression during the bevacizumab treatment in this group. This increase 
disappeared after VI cycles (p = 0.08) of therapy.  
  
Figure 5. Evaluation of IL10+cells at T0 and after III and VI cycles of treatment in bevacizumab patients 
and fold increase of the percentage of IL10+cells after III and VI cycles of therapy compared with T0 
(%IL10 III or %IL10 VI/%IL10 T0) in R and N-R patients belonging to the Bev group. 
4. Discussion 
Multi-treated progressive ovarian cancer still remains the most challenging disease setting for 
gynecologic oncologists, and so far, no global consensus has been met about how/how long patients 
should be continued to be treated [16]. Indeed, all these patients progressively develop 
pharmacoresistance for the majority of conventional chemotherapy drugs, and the only option left (if they 
are not eligible for phase I clinical trials) is to retreat them with previously adopted compounds [17]. 
Among biological agents that have obtained FDA/EMA approval in compassionate ovarian cancer 
setting, bevacizumab has been the first to enter into clinical practice after showing its ability to 
improve patients’ quality of life and also reduce paracentesis frequency for women suffering 
malignant ascites [5].  
The effects of bevacizumab on patients’ immune system are still not completely elucidated, 
although a strong rationale about the interplay between its ligand (VEGF) and the host’s immune 
response suppression has already been shown [18]. In particular, three different mechanisms related 
to VEGF-mediated immunosuppression have been assessed so far: inhibition of dendritic cell 
maturation [19–21], reduction of T cell tumor infiltration [22], and promotion of inhibitory cells in the 
tumor microenvironment [23]. 
In this scenario, the present study adds new evidence to the body of knowledge concerning the 
immune effects of bevacizumab in advanced cancer patients by showing that (1) ovarian cancer 
patients not treated with bevacizumab-based chemotherapy seem to have a more 
immunosuppressive profile with the presence of a rTreg population that persists until the end of III 
cycles of therapy; (2) patients that clinically respond to bevacizumab treatment show a discrete 
population of effector T cells at the beginning of therapy that is maintained throughout the treatment; 
(3) Tregs are mainly represented by non-suppressive regulatory T cells in clinically responding 
bevacizumab patients compared with nonresponding patients and are also stably maintained in this 
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ratio (nsT reg > sup T reg) throughout the treatment; (4) after three cycles of treatment, 
nonresponding bevacizumab patients produce more immunosuppressive IL-10 cytokine compared 
with responding patients.  
It should be pointed out that these results were obtained by comparing two groups of patients 
that were matched for all clinical characteristics. Particularly important is to notice that the 
performance status was similar among the two groups; this variable has been significantly associated 
with the immunological effects and response to several therapies [24]  
Other authors have observed an impact of bevacizumab-based regimens on the 
immunosuppressive status of cancer patients in different cancer settings. In particular, it was recently 
reported that, for glioblastoma patients subjected to radiation plus temozolomide (TMZ) and 
bevacizumab, the absolute number of peripheral Tregs significantly decreased following treatment [25]. 
Furthermore, the addition of bevacizumab to standard radiation and TMZ appeared to decrease the 
number of circulating Tregs compared with radiation plus TMZ alone. On the contrary, they also 
noticed a significant decrease in the absolute number of cytotoxic CD8 (CD107a+), effector memory 
CD8, and naïve CD4 T cells in the group of bevacizumab-treated patients.  
Our results follow and confirm the original observation by our group [6] in which a significant 
reduction of Tregs and an increase in the proportion and function of effector CD8 T cells were found 
in an end-of-life ovarian cancer patient treated with low-dose intraperitoneal bevacizumab for 
malignant ascites.  
We also showed that responding bevacizumab-treated patients reported a higher percentage of 
circulating CD4 effector T cells compared with nonresponding bevacizumab patients, confirming 
what has already been observed in metastatic colorectal cancer [2]. This data has key implications in 
the current panorama of oncological clinical approach. Indeed, it is reasonable to suggest that the 
circulating effector T cells recruited and sustained by bevacizumab treatment, thanks to its ability to 
restore tumor microvascular normalization [13], could be expanded by the administration of 
checkpoint inhibitor agents, thus giving a strong biological rationale for the combination of 
immunotherapy with bevacizumab antiangiogenetic therapy. In support of this consideration, tumor 
tissue derived from metastatic renal cell carcinoma (mRCC) patients treated with anti-PD-L1 
atezolizumab plus bevacizumab was recently found to show an increase in intratumoral CD8 T cells 
as well as an increase in intratumoral MHC-I, Th1 and T-effector markers, and chemokines. Trafficking 
lymphocytes also increased in tumors following bevacizumab and combination treatment [26]. 
We finally observed that bevacizumab responding patients showed significant lower circulating 
immunosuppressive IL-10 cytokine levels compared with non-responding patients, thus confirming 
the effect of bevacizumab in reducing patients’ immune suppression. A similar finding was recently 
obtained in breast cancer neoadjuvant setting [27]. Patients treated with bevacizumab-included 
neoadjuvant chemotherapy showed a global decrease in circulating cytokines levels, such as VEGF-A, 
IL-12, IP-10, and IL-10. In addition, the decrease in IL-10 serum levels was confirmed to be even 
greater in response to bevacizumab treatment in metastatic colorectal cancer setting [28].  
To our knowledge, this is the first study analyzing the immunological effects of bevacizumab-
based treatment in women with advanced ovarian cancer in relation to their clinical response.  
However, several significant limitations are present in this study. The first is the restricted 
number of patients that were retrospectively and not randomized selected. Moreover, there were no 
data regarding the immune fitness of the patients at diagnosis before the beginning of all therapies. 
Finally, although no differences in clinicopathological variables were identified, the two groups 
analyzed showed several differences in their immunological signature at T0. These differences could 
be ascribed to the several chemotherapy treatments (e.g., taxol, bemcitabine, pegilated liposomal, 
doxorubicin etc.) that differently impact the immunological system [29], together with the capacity 
of the immunological signature of each patient to differently respond to the same environmental 
factor, such as chemotherapy and surgery. In this setting, a discrete population of effector CD4 T cell 
is present in any case in both populations of patients independently from previous treatment. This 
cell subset is the one that appears to be affected by the bevacizumab regimen, and this could impact 
clinical outcome. 
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Another important point is the occurrence of leukopenia in multi-treated patients, which 
represents an important prognostic factor in patients with advance malignances [30]. In our setting, 
patients were affected by mild/moderate leukopenia that was non-clinically significant.  
The strengths of this study can be summarized as follows: (1) the population involved was 
homogeneous for histology and clinical stage; (2) the patients belonging to the two groups 
(bevacizumab-treated and control) were matched for age, tumor grading, FIGO stage, type of 
primary treatment strategy (primary debulking surgery versus neoadjuvant chemotherapy followed 
by interval debulking surgery), tumor residual at first surgery, and type of recurrence at the time of 
blood sampling, thus minimizing selection bias; (3) blood sampling was carried out for all patients at 
the same times of treatment, i.e., at T0 and after three and six cycles of therapy. 
5. Conclusions 
In conclusion, this study sheds a light on the strong need to routinely include 
immunomonitoring in oncological clinical protocols of patients at follow-up during the course of 
antiangiogenetic therapy administrations, with the final aim being to identify early the subset of 
patients who can mostly benefit from its adoption. Furthermore, the study provides a first rationale 
regarding the positive immunologic impact of combining bevacizumab with checkpoint inhibitors. 
Confirmatory studies carried out on larger cancer patient populations are warranted.  
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